Last updated: 21 January 2021 at 7:42am EST

Partners Gp Viii, L.L.C.Pol... Net Worth




The estimated Net Worth of Partners Gp Viii, L.L.C.Pol... is at least $6.64 Million dollars as of 21 July 2020. Partners Pol owns over 36,111 units of Pandion Therapeutics stock worth over $6,642,791 and over the last 4 years Partners sold PAND stock worth over $0.

Partners Pol PAND stock SEC Form 4 insiders trading

Partners has made over 1 trades of the Pandion Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Partners bought 36,111 units of PAND stock worth $649,998 on 21 July 2020.

The largest trade Partners's ever made was buying 36,111 units of Pandion Therapeutics stock on 21 July 2020 worth over $649,998. On average, Partners trades about 36,111 units every 0 days since 2020. As of 21 July 2020 Partners still owns at least 110,621 units of Pandion Therapeutics stock.

You can see the complete history of Partners Pol stock trades at the bottom of the page.



Insiders trading at Pandion Therapeutics

Over the last 4 years, insiders at Pandion Therapeutics have traded over $0 worth of Pandion Therapeutics stock and bought 1,743,632 units worth $30,815,954 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Kol..., and Daniel J. Becker. On average, Pandion Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $9,518,646. The most recent stock trade was executed by Daniel J. Becker on 19 November 2020, trading 197,716 units of PAND stock currently worth $2,989,466.



What does Pandion Therapeutics do?



What does Pandion Therapeutics's logo look like?

Pandion Therapeutics, Inc. logo

Complete history of Partners Pol stock trades at Pandion Therapeutics

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
21 Jul 2020 Partners Gp Viii, L.L.C.Pol...
Buy 36,111 $18.00 $649,998
21 Jul 2020
110,621


Pandion Therapeutics executives and stock owners

Pandion Therapeutics executives and other stock owners filed with the SEC include: